Inventor · disambiguated record
Jeffrey Zuber
Also filed as: ZUBER JEFFREY
2 granted patents·23 pending applications·6 citations·filing 2021–2024
48Inventor score
Files withALNYLAM PHARMACEUTICALS INC25
Top patents by PatentIndex Score
25 records- 0187US11613751B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 28, 2023·6 cites·30 claims
- 0275US12416006B2Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Sep 16, 2025·0 cites·23 claims
- 0373US2024254491A1BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0473US2025084418A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0573US2024344066A1BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0667US2024309375A1Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disordersALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0765US2024254493A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0865US2024132895A1GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0965US2025034567A1Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1064US2025043289A13-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1164US2024132886A1COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1263US2024271144A1Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1362US2023416736A1Mucin 5b (muc5b) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1462US2024117348A1COAGULATION FACTOR X (F10) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1560US2025283079A1ACTIN-BINDING LIM PROTEIN 3 (ABLIM3) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1656US2025051767A1iRNA Compositions and Methods for Silencing MYLIPALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1756US2024309370A1Metabolic disorder-associated target gene irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1856US2024254484A1SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR 6 (STAT6) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1955US2025283071A1Modified double stranded oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2055US2022380762A1HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2155US2025171777A1Microtubule Associated Protein Tau (MAPT) iRNA Agent Compositions and Methods of Use ThereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2254US2025136978A1iRNA Compositions and Methods for Silencing ANGPTL4ALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2354US2024117349A1iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP)ALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2452US2024209374A1iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEINALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2552US2023203486A1MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeffrey Zuber files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →